期刊
CURRENT MEDICINAL CHEMISTRY
卷 27, 期 42, 页码 7264-7288出版社
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/0929867327666200102115720
关键词
Anticancer agents; multi-target; protein kinase inhibitor; histone deacetylase inhibitor; combination therapy; hybrids; receptor tyrosine kinases
资金
- Natural Science Foundation of China [21977058, 81302628, 81473089]
- Project of Jiangsu Six Peaks of Talent, China [2014-SWYY-044, 2016-SWYY-CXTD-008]
- Jiangsu Province Postdoctoral Science Foundation [2018T110533, 2016M590488, 1601136B]
- Project of Jiangsu 333 high-level talents, Applied Research Projects of Nantong City [MS12018079, JC2018125]
- Jiangsu Province Innovation Project of Postgraduate Training [KYCX19_2086]
Protein Kinase Inhibitors (PKIs) and Histone Deacetylase Inhibitors (HDACIs) are two important classes of anticancer agents and have provided a variety of small molecule drugs for the treatment of various types of human cancers. However, malignant tumors are of a multifactorial nature that can hardly be cured by targeting a single target, and treatment of cancers hence requires modulation of multiple biological targets to restore the physiological balance and generate sufficient therapeutic efficacy. Multi-target drugs have attracted great interest because of their advantages in the treatment of complex cancers by simultaneously targeting multiple signaling pathways and possibly leading to synergistic effects. Synergistic effects have been observed in the combination of kinase inhibitors, such as imatinib, dasatinib, or sorafenib, with an array of HDACIs including vorinostat, romidepsin, or panobinostat. A considerable number of multi-target agents based on PKIs and HDACIs have been developed. In this review, we summarize the recent literature on the development of multi-target kinase-HDAC inhibitors and provide our view on the challenges and future directions on this topic.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据